These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9124849)

  • 41. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
    Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
    Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats.
    Kim JC; Bae CS; Kim SH; Yun HI; Park SC; Shin HC; Han J; Chung MK
    Toxicol Lett; 2003 Apr; 142(1-2):103-9. PubMed ID: 12765244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
    Takizawa T; Hasimoto K; Itoh N; Yamashita S; Owen K
    Hum Exp Toxicol; 1999 Jan; 18(1):38-45. PubMed ID: 10025367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.
    Zix JA; Geerdes-Fenge HF; Rau M; Vöckler J; Borner K; Koeppe P; Lode H
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1668-72. PubMed ID: 9257738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Grepafloxacin--a new fluoroquinolone.
    Med Lett Drugs Ther; 1998 Jan; 40(1019):17-8. PubMed ID: 9465856
    [No Abstract]   [Full Text] [Related]  

  • 46. Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones.
    Blum RA
    Am J Med; 1992 Apr; 92(4A):18S-21S. PubMed ID: 1316065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal clearance of lomefloxacin is decreased by furosemide.
    Sudoh T; Fujimura A; Shiga T; Sasaki M; Harada K; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1994; 46(3):267-9. PubMed ID: 8070509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of age and gender on the pharmacokinetics of moxifloxacin.
    Sullivan JT; Lettieri JT; Liu P; Heller AH
    Clin Pharmacokinet; 2001; 40 Suppl 1():11-8. PubMed ID: 11352437
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats.
    Park YH; Jung BH; Chung BC; Park J; Mitoma C
    Drug Metab Dispos; 1997 Sep; 25(9):1101-3. PubMed ID: 9311628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and tolerance of a new fluoroquinolone antimicrobial drug after single oral doses in healthy volunteers.
    Tanaka M; Tamura K; Atarashi S; Kubo Y; Oliver SD; Bentley M; Hakusui H
    Xenobiotica; 1995 Nov; 25(10):1119-25. PubMed ID: 8578768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.
    Mattina R; Bonfiglio G; Cocuzza CE; Gulisano G; Cesana M; Imbimbo BP
    Chemotherapy; 1991; 37(6):389-97. PubMed ID: 1662127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens.
    Knoll U; Glünder G; Kietzmann M
    J Vet Pharmacol Ther; 1999 Aug; 22(4):239-46. PubMed ID: 10499235
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of enrofloxacin after intravenous and intramuscular injection in rabbits.
    Cabanes A; Arboix M; Garcia Anton JM; Reig F
    Am J Vet Res; 1992 Nov; 53(11):2090-3. PubMed ID: 1334640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Grepafloxacin (Raxar)].
    Friis HM
    Ugeskr Laeger; 1998 Jul; 160(30):4438-41. PubMed ID: 9691842
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction.
    Stass H; Kubitza D; Halabi A; Delesen H
    Br J Clin Pharmacol; 2002 Mar; 53(3):232-7. PubMed ID: 11874385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.
    Randinitis EJ; Koup JR; Rausch G; Abel R; Bron NJ; Hounslow NJ; Vassos AB; Sedman AJ
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2536-42. PubMed ID: 11502526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intramuscular administration of enrofloxacin in goats.
    Rao GS; Ramesh S; Ahmad AH; Tripathi HC; Sharma LD; Malik JK
    Vet Res Commun; 2001 Apr; 25(3):197-204. PubMed ID: 11334149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of terbium-sensitized luminescence for the determination of grepafloxacin in human urine and serum.
    Ocaña JA; Callejón M; Barragán FJ
    J Pharm Sci; 2001 Oct; 90(10):1553-7. PubMed ID: 11745713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of cimetidine on the pharmacokinetics of temafloxacin.
    Sörgel F; Granneman GR; Stephan U; Locke C
    Clin Pharmacokinet; 1992; 22 Suppl 1():75-82. PubMed ID: 1319874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.